The Leadership Team
Robin Y. Smith, CEO
Robin Y. Smith brings over 20 years of startup, science, and entrepreneurial experience to ORIG3N. In his previous roles as founder of three successful enterprises, Robin returned over 78% IRR to investors at two VC-backed companies. As the global head of R&D for PerkinElmer, he managed teams as large as 500 people. Robin is a visionary and strategist who is passionate about building high-energy startup organizations.
Kate Blanchard, COO
Kate Blanchard is focused on driving successful outcomes for ORIG3N, with over 15 years of experience in growing high-tech companies through operations, marketing, and finance. She served as VP of Marketing & Product Management at ArtusLabs and led the worldwide TIBCO Spotfire business for PerkinElmer. She holds a BA from The Ohio State University and an MBA from the University of North Carolina.
Marcie Glicksman, PhD, Chief Scientific Officer
Dr. Marcie Glicksman has been in the drug discovery field for over 20 years, and has extensive experience in assay development, high throughput screening, and chemical databases. Before joining ORIG3N, she was Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN), part of the Harvard NeuroDiscovery Center. She holds a BA from Brown University and a PhD in Neuroscience from Washington University.
Michael Fang, MD, Chief Medical Officer
Michael Fang is a physician and entrepreneur with a dual specialty in Internal Medicine and Geriatric Medicine. A founder of CETA, a health information technology company, he led the company in 1,500% growth over 3 years. In 2015, CETA ranked #297 on Inc. Magazine’s 5000 fastest-growing private US companies. Formerly, Michael co-founded IMOSPHERE, Inc. He holds a BA and a medical degree, both from Northwestern University.